ESTRO 2023 - Abstract Book

S855

Digital Posters

ESTRO 2023

Materials and Methods We retrospectively analyzed the outcomes of 7 patients (4 women, 3 men) treated at our institution for a total of 9 keloids between May 2021 and September 2022. All patients had undergone one or more previous surgical treatments for recurrent keloids Radiation therapy with a 6-MeV electron beam began 24 hours after complete excision of the keloid. A silicone bolus of 0.5-1 cm was applied to the surgical keloid scar to achieve an adequate radiation dose on the skin surface. For keloids located in the earlobe, we prepared a personalized high-density bolus (eXaSkin) the day before surgery to reduce the dose to the external auditory canal and mastoid bone (Figure 1A and 1D). A three-fraction regimen of 1950-2100 cGy (650-700 cGy/die) was used. Results The mean age was 30 years (range 18-41), and 3/6 of the patients were Caucasian. Five keloids were located in the earlobes, 2 in the chest, 1 in the axilla, and 1 in the shoulder. Factors contributing to keloid formation included piercing lesions (5/9), surgical scars (2/9 lesions), and in 1 patient there was a family history Treatments were well tolerated with no acute toxicity. The median follow-up time was 3 months, no recurrences occurred in all patients, and good cosmetic results were reported (Figure 1).

Conclusion Radiotherapy is a valid option to reduce the recurrence of keloids after failure of surgical excision and steroid therapy. It also appears to improve cosmetic outcome. Multidisciplinary collaboration is required to achieve optimal timing between surgery and radiotherapy. Prolonged follow-up is needed to confirm these results.

PO-1070 Management of cardiac implantable devices during radiation therapy: a single centre experience.

R. Villa 1,2 , J. Franzetti 1,2 , D. Zerini 1 , C. Lorubbio 1,2 , F. Cattani 3 , N. Colombo 4 , M. Civelli 4 , G. Lamantia 4 , A. Colombo 4 , G. Bacchiani 4 , C.A. Meroni 4 , B.A. Jereczek-Fossa 1,2 1 IEO, European Institute of Oncology, IRCCS, Division of Radiation Oncology, Milan, Italy; 2 University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy; 3 IEO, European Institute of Oncology, IRCCS, Unit of Medical Physics, Milan, Italy; 4 IEO, European Institute of Oncology, IRCCS, Division of Cardiology, Milan, Italy Purpose or Objective Over the past few years, an increasing number of cardiac implantable electronic devices (CIEDs), including both pacemakers (PM), implantable cardiac defibrillators (ICD) and loop recorders (LR), has been used to manage various type of cardiac arrhythmias. Considering that the number of radiation therapy (RT) treatments is increasing, to ensure a safe management of all the devices has become mandatory. The aim of this work is to explain how CIEDs are managed in a single centre experience. Materials and Methods We evaluated and described our activity from the end of June 2010 to September 2021; the clinical data was downloaded from a database including all the patients with CIEDs treated in our department. Results 215 patients with CIEDs were treated in our Institute in the period in analysis: 149 patients with PM, 65 with ICD and one with LR. 40 radiation treatments were re-irradiations. Beam energy for all the therapies was X6 MV; 68 patients were